Evaluating the Genetic Factors That May Lead to Sudden Cardiac Arrest (The GenSCA Study)
Death, Sudden, Cardiac
|Study Design:||Observational Model: Case Control|
|Official Title:||Genomics of Sudden Cardiac Arrest|
- Genetic factors that may predispose people to develop SCA [ Time Frame: Measured throughout the study ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||September 2007|
|Estimated Study Completion Date:||August 2014|
|Estimated Primary Completion Date:||August 2014 (Final data collection date for primary outcome measure)|
European American people who have experienced SCA.
European American people who have not experienced SCA.
African American people who have experienced SCA.
African American people who have not experienced SCA.
SCA occurs when the heart suddenly and unexpectedly stops beating. When this happens, blood stops flowing to the brain and other vital organs. Ninety-five percent of people who experience SCA die from it, most within minutes. SCA is usually caused by abnormal heart rhythms, known as arrhythmias, which can be triggered by several factors, including coronary artery disease, physical stress, and structural changes in the heart. Certain genetic factors may also increase the likelihood of experiencing SCA. Study researchers will analyze genetic samples from people affected by SCA and people unaffected by SCA to identify and characterize genetic variations that are associated with an increased risk of SCA in European Americans and African Americans.
This study will examine previously collected blood samples from people who have experienced SCA and were participants in the Cardiac Arrest Blood Study (CABS) and the Cardiovascular Health Study (CHS). These participants will not attend any study visits or be contacted by study researchers. People who experience SCA in the first 4 years of this study will have blood drawn from paramedics at the time of SCA. If these participants survive, they will be asked whether study researchers can review their medical records. Study researchers will also examine previously collected blood samples from participants who have not experienced SCA and were participants in CABS, CHS, and the Heart and Vascular Health Study. These participants will not attend any study visits or be contacted by study researchers. Study researchers will also enroll a new control group of people who have not experienced SCA. These participants will attend one study visit for blood collection and a medical record review.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00661128
|United States, Washington|
|Cardiovascular Health Research Unit, University of Washington|
|Seattle, Washington, United States, 98101|
|Principal Investigator:||Nona Sotoodehnia, MD, MPH||University of Washington|